Beximco manufacture and sell generic drug formulations and active pharmaceutical ingredients (APIs). The company’s manufacturing facility in Bangladesh’s capital Dhaka is able to produce various dosage forms including tablets, capsules, liquids, inhalers and injectables. It has now formed an agreement with Malaysia’s BioCare, representing the company’s first overseas manufacturing deal.

The joint venture is part of the Malaysian Government’s economic transformation programme, which aims to increase investment in the Malaysian pharmaceutical industry, improve manufacturing facilities and promote local production.

Beximco will provide full technical support to establish a Malaysian manufacturing base for a range of generic, specialized pharmaceutical products, including inhalers. The facility will be based at Seri Iskandar Pharmaceutical Park, Perak, in the northwest of Malaysia. BioCare will fund and operate the facility, and offer Beximco 30% equity shares in the joint venture in return for its technical support.

Beximco’s Managing Director Nazmul Hassan commented that the joint venture could help to address unmet medical needs in Malaysia, while facilitating the company’s goal to strengthen their presence in the global generics market.

The facility for producing standard dose inhalers has already received GMP approval from Malaysia’s Ministry of Health. Products manufactured in the new facility should reach the market within the year – although Beximco say they do not expect to receive significant profit contributions from the facility in the short term. 

Related articles
Biosimilar production in Malaysia

Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2017 Pro Pharma Communications International. All Rights Reserved.